{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Agost-Beltran L"],"funding":["Jaume I University"],"pagination":["2523"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9026863"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(8)"],"pubmed_abstract":["Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested. A huge effort was then carried out by the scientific community to design, synthesize and test new small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these compounds can be classified into two main groups: one corresponds to modified peptides displaying an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group including chemical compounds that do not have a peptide framework. Although a drug including a SARS-CoV-2 main prote"],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["Advances in the Development of SARS-CoV-2 Mpro Inhibitors."],"pmcid":["PMC9026863"],"funding_grant_id":["(UJI-2021-71); SomUJIContraCovid (crowdfunding campaign)"],"pubmed_authors":["Fernandez-de-la-Pradilla A","Agost-Beltran L","Gonzalez FV","Rodriguez S","de la Hoz-Rodriguez S","Bou-Iserte L"],"additional_accession":[]},"is_claimable":false,"name":"Advances in the Development of SARS-CoV-2 Mpro Inhibitors.","description":"Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested. A huge effort was then carried out by the scientific community to design, synthesize and test new small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these compounds can be classified into two main groups: one corresponds to modified peptides displaying an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group including chemical compounds that do not have a peptide framework. Although a drug including a SARS-CoV-2 main prote","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-20T00:18:33.732Z","creation":"2025-02-19T01:53:45.811Z"},"accession":"S-EPMC9026863","cross_references":{"pubmed":["35458721"],"doi":["10.3390/molecules27082523"]}}